ZENOCUTUZUMAB

UNII:	AE72RB1W1X
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	ZENOCUTUZUMAB
GSRS Full Record:	AE72RB1W1X i

1969309-56-5
BIZENGRI
Immunoglobulin G1, bispecific, anti-(human epidermal growth factor receptors, HER2 and HER3) (humanized clone MCLA-128 γ1-chain), disulfide with humanized clone MCLA-128 light chain, dimer
Immunoglobulin G1-kappa, anti-(Homo sapiens Receptor tyrosine-protein kinase erbB-3 (Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, EC=2.7.10.1)) and anti-(Homo sapiens Receptor tyrosine-protein kinase erbB-2 (Metastatic lymph node gene 19 protein, Tyrosine kinase-type cell surface receptor HER2, CD340 antigen)); humanized monoclonal antibody, bispecific; γ1 heavy chain anti-ERBB3 (1-453) [Homo sapiens VH (IGHV1-2*02 –(IGHD)-IGHJ4*01 [8.8.17] (1-124) -Homo sapiens IGHG1*03 {CH3[L 11 >K(358),T 26 >K(373),K107 >del(454)]} (125-453)] (227-214')-disulfide with κ light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 – IGKJ1*01)[6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (233-230'':236-233'')-bisdisulfide with γ1 heavy chain anti-ERBB2 (1''-450'') [humanized VH (Homo sapiens IGHV1-46*01 (84%) –(IGHD)-IGHJ4*01 [8.8.14] (1''-121'') -Homo sapiens IGHG1*03 {CH3[L 11 >D(355''),L 24 >E(372''),K107 >del(451'')]} (122''-450'')] (224''-214''')-disulfide with κ light chain (1'''-214''') [Homo sapiens V-KAPPA (IGKV1-39*01 –IGKJ1*01)[6.3.9] (1'''-107''') -Homo sapiens IGKC*01 (108'''-214''')]. (Source: USAN Program chemical consultant)
MCLA-128
MCLA-128 (IGG1 BISPECIFIC ANTIBODY WITH ENHANCED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) ACTIVITY TARGETING HER2 AND HER3 RECEPTORS.)
MCLA128
ZENOCUTUZUMAB [USAN]
Zenocutuzumab
Zenocutuzumab [WHO-DD]
Zenocutuzumab zbco [WHO-DD]
Zenocutuzumab-ZBCO
zenocutuzumab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

ZENOCUTUZUMAB

Synonyms and Mappings

Resources